Complix to accelerate development of CPABs against intracellular disease targets

Published on October 30, 2012 at 6:55 AM · No Comments

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). The grant will allow Complix to accelerate the development of its unique cell penetrating Alphabodies (CPABs), against a range of intracellular disease targets, including cancer.

Alphabodies represent a novel therapeutic development platform with the potential to address a vast number of disease targets that are currently considered "undruggable" by the two main classes of therapeutic drugs: small chemical drugs and therapeutic antibodies. In particular their ability to act on intracellular protein targets represents a major medical and commercial opportunity.

During the past year, Complix has generated a wealth of data demonstrating the attractive properties of CPABs that are capable of acting on intracellular disease targets. These results show that CPABs are taken up effectively by tumor cells. Once inside cancer cells the CPABs can act on an oncogenic target protein and block its function, thereby inducing apoptosis (cell death).

Dr Mark Vaeck, CEO of Complix, said: "We are delighted to have received this funding from IWT, which is a clear endorsement of the power of our unique CPAB platform. The results that we have generated so far indicate this platform has the potential to transform the pharmaceutical industry's ability to address the most interesting class of potential drug targets, namely intracellular protein-protein interactions (PPIs).

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post